Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2013

01-04-2013 | Original Research

IL-10— and IL-20—Expressing Epithelial and Inflammatory Cells are Increased in Patients with Ulcerative Colitis

Authors: Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Luis Llorente, Jesús K. Yamamoto-Furusho

Published in: Journal of Clinical Immunology | Issue 3/2013

Login to get access

Abstract

Interleukin (IL)-20, a pro-inflammatory cytokine, is a recently discovered member of the IL-10 family. This cytokine has been described in inflammatory diseases such as psoriasis and asthma. However, IL-20 expression in ulcerative colitis (UC) patients has not been yet described. The aim of this study was to evaluate IL-20 and IL-10 gene and protein expression and their receptors in the mucosa from UC patients. Forty UC patients and 18 non-inflamed controls were studied. IL-10, IL-20, IL-10R1, IL-10R2, IL-20R1 and IL-20R2 gene expression was determined by real time RT-PCR in colonic biopsies. Protein expression was evaluated by immunohistochemistry. Patients in remission had significantly higher IL-10 gene expression in mucosa compared with active patients and controls. Conversely, IL-10R1/B gene expression was decreased in remission compared with active UC patients and controls. IL-20 gene expression was lower in colonic mucosa from UC patients in remission compared with controls and active patients. IL-20R1/B mRNA expression was higher in remission compared with active UC patients and controls. IHQ analysis showed an increased IL-10—, IL-20—, and IL-20R2—producing cells in active UC patients. IL-10—, IL-20— and IL-20R2—expressing epithelial and inflammatory cells were increased in active UC patients, meanwhile IL-20R1 was up-regulated only on inflammatory infiltrates vs. controls. This is the first depiction of the presence of IL-20 and its receptors in UC. Much remains to be learned however, about the pathogenic mechanisms that lead to IBD. This cytokine/receptor imbalance may be implicated in the pathogenesis of UC.
Literature
1.
go back to reference Podolsky DK. Inflammatory bowel disease. N England J Med. 2002;347:417–29.CrossRef Podolsky DK. Inflammatory bowel disease. N England J Med. 2002;347:417–29.CrossRef
2.
go back to reference Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol. 2004;10:620–5.PubMed Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol. 2004;10:620–5.PubMed
3.
go back to reference Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;23:71–109.CrossRef Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;23:71–109.CrossRef
5.
go back to reference Blumberg H, Conklin D, Xu WF, et al. Interleukin-20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9–19.PubMedCrossRef Blumberg H, Conklin D, Xu WF, et al. Interleukin-20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9–19.PubMedCrossRef
6.
go back to reference Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;15:2229–40. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;15:2229–40.
7.
go back to reference Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;4:16–23.CrossRef Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;4:16–23.CrossRef
8.
go back to reference Chen WY, Cheng BC, Jiang MJ, et al. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2090–105.PubMedCrossRef Chen WY, Cheng BC, Jiang MJ, et al. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2090–105.PubMedCrossRef
9.
go back to reference Li HH, Cheng HH, Sun KH, et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol. 2008;129:277–85.PubMedCrossRef Li HH, Cheng HH, Sun KH, et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol. 2008;129:277–85.PubMedCrossRef
10.
go back to reference Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010;62:3311–21.PubMedCrossRef Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010;62:3311–21.PubMedCrossRef
11.
go back to reference Rich BE, Kupper TS. Cytokines: IL-20 – a new effector in skin inflammation. Curr Biol. 2001;11:531–4.CrossRef Rich BE, Kupper TS. Cytokines: IL-20 – a new effector in skin inflammation. Curr Biol. 2001;11:531–4.CrossRef
12.
go back to reference Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008;83:1181–93.PubMedCrossRef Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008;83:1181–93.PubMedCrossRef
13.
go back to reference Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.PubMedCrossRef Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.PubMedCrossRef
14.
go back to reference Wegenka UM. IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev. 2010;21:353–63.PubMedCrossRef Wegenka UM. IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev. 2010;21:353–63.PubMedCrossRef
15.
go back to reference Camarillo GF, Furuzawa-Carballeda J, Martínez-Benítez B, et al. Role of the interleukin 24 in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17:2209–10.PubMedCrossRef Camarillo GF, Furuzawa-Carballeda J, Martínez-Benítez B, et al. Role of the interleukin 24 in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17:2209–10.PubMedCrossRef
16.
go back to reference Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, et al. Colonic epithelial upregulation of Interleukin 22 in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16:1819–998.CrossRef Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, et al. Colonic epithelial upregulation of Interleukin 22 in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16:1819–998.CrossRef
Metadata
Title
IL-10— and IL-20—Expressing Epithelial and Inflammatory Cells are Increased in Patients with Ulcerative Colitis
Authors
Gabriela Fonseca-Camarillo
Janette Furuzawa-Carballeda
Luis Llorente
Jesús K. Yamamoto-Furusho
Publication date
01-04-2013
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9843-4

Other articles of this Issue 3/2013

Journal of Clinical Immunology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine